A detailed history of Qube Research & Technologies LTD transactions in Agios Pharmaceuticals, Inc. stock. As of the latest transaction made, Qube Research & Technologies LTD holds 84,417 shares of AGIO stock, worth $4.7 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
84,417
Previous 24,830 239.98%
Holding current value
$4.7 Million
Previous $1.07 Million 250.47%
% of portfolio
0.01%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$41.19 - $49.72 $2.45 Million - $2.96 Million
59,587 Added 239.98%
84,417 $3.75 Million
Q2 2024

Aug 14, 2024

SELL
$27.55 - $48.83 $507,305 - $899,155
-18,414 Reduced 42.58%
24,830 $1.07 Million
Q1 2024

May 14, 2024

SELL
$21.32 - $34.81 $1.58 Million - $2.59 Million
-74,268 Reduced 63.2%
43,244 $1.26 Million
Q4 2023

Feb 13, 2024

BUY
$19.97 - $24.53 $2.35 Million - $2.88 Million
117,512 New
117,512 $2.62 Million
Q4 2022

Feb 14, 2023

BUY
$24.81 - $31.52 $969,103 - $1.23 Million
39,061 New
39,061 $1.1 Million
Q2 2022

Aug 15, 2022

BUY
$17.06 - $31.42 $841,655 - $1.55 Million
49,335 Added 139.11%
84,801 $1.88 Million
Q1 2022

May 09, 2022

BUY
$26.68 - $34.81 $32,683 - $42,642
1,225 Added 3.58%
35,466 $1.03 Million
Q4 2021

Feb 01, 2022

BUY
$29.58 - $49.78 $1.01 Million - $1.7 Million
34,241 New
34,241 $1.13 Million
Q4 2020

Feb 16, 2021

SELL
$33.21 - $46.54 $577,355 - $809,097
-17,385 Closed
0 $0
Q3 2020

Nov 12, 2020

BUY
$33.87 - $55.93 $588,829 - $972,343
17,385 New
17,385 $608,000
Q2 2020

Aug 14, 2020

SELL
$34.45 - $53.48 $448,160 - $695,721
-13,009 Closed
0 $0
Q1 2020

May 15, 2020

BUY
$31.52 - $53.81 $410,043 - $700,014
13,009 New
13,009 $462,000

Others Institutions Holding AGIO

About AGIOS PHARMACEUTICALS, INC.


  • Ticker AGIO
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 54,818,000
  • Market Cap $3.05B
  • Description
  • Agios Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of medicines in the field of cellular metabolism and adjacent areas of biology. The company offers PYRUKYND (mitapivat) an activator of both wild-type and a variety of mutant pyruvate kinase, PK, enzymes for the treatment of hemolytic anemias; and ...
More about AGIO
Track This Portfolio

Track Qube Research & Technologies LTD Portfolio

Follow Qube Research & Technologies LTD and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Qube Research & Technologies LTD, based on Form 13F filings with the SEC.

News

Stay updated on Qube Research & Technologies LTD with notifications on news.